Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 53, 777-783, February 15, 1993]
© 1993 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murphy, S. E.
Right arrow Articles by Coletta, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murphy, S. E.
Right arrow Articles by Coletta, K. A.

Two Types of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone Hemoglobin Adducts, from Metabolites Which Migrate into or Are Formed in Red Blood Cells1

Sharon E. Murphy2 and Kristin A. Coletta

American Health Foundation, Naylor Dana Institute for Disease Prevention, Valhalla, New York 10595

The tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), is considered to play an important role in the induction of lung cancer in tobacco users. In rats treated with [5-3H]NNK, 20 to 40% of the tritium bound to hemoglobin (Hb) is released by base hydrolysis as 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB). This HPB-releasing adduct has been quantified in tobacco users and is considered a biochemical marker for uptake and activation of tobacco-specific nitrosamines. In this paper we report the formation of this adduct in red blood cells (RBC) cultured for 2 h with hepatocytes and 5 µM NNK (6.35 ± 0.21 fmol HPB/mg Hb). The HPB-releasing adduct was not formed in RBC in the absence of hepatocytes (<0.5 fmol/mg Hb). Therefore, the HPB-releasing adduct must form from a pyridyloxobutylating metabolite of NNK which traveled out of the hepatocytes and into RBC where it reacted with Hb. Other distinct Hb adducts were formed when NNK was incubated with RBC alone. 4-Oxo-4-(3-pyridyl)butyric acid was detected by radio flow high-performance liquid chromatography in the media of these incubations. The Hb isolated from RBC incubated with [C3H3]NNK contained as much as 10 times more covalently bound tritium than the Hb from [5-3H]NNK-treated cells. [C3H3]-1-Methylhistidine and [C3H3]-S-methylcysteine were formed when [C3H3]NNK was incubated with the 25,000 x g supernatant from RBC. This supernatant contains 50 mg Hb/ml. We propose that Hb mediates {alpha} hydroxylation of NNK at the methylene carbon. The {alpha}-hydroxynitrosamine formed decomposes to methanediazohydroxide and 4-oxo-1-(3-pyridyl)butanal. The former would methylate nucleophilic sites in Hb, i.e., cysteine and histidine. The latter would bind to Hb or be further oxidized to 4-oxo-4-(3-pyridyl)butyric acid. The ability of the RBC to activate NNK to Hb-binding species stresses the importance of understanding how a particular adduct is formed prior to its use as a biochemical marker or internal dose monitor.

1 This study was supported by Grants CA-32617 and CA-29580 from the National Cancer Institute. This is Paper 7 in "Hemoglobin Adducts as Carcinogen Dosimeters."

2 To whom requests for reprints should be addressed.

Received 8/20/92. Accepted 12/ 2/92.




This article has been cited by other articles:


Home page
CarcinogenesisHome page
P. Upadhyaya, S. G. Carmella, F.P. Guengerich, and S. S. Hecht
Formation and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers in vitro in mouse, rat and human tissues
Carcinogenesis, June 1, 2000; 21(6): 1233 - 1238.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1993 by the American Association for Cancer Research.